211 related articles for article (PubMed ID: 16740078)
1. Evaluation of protection against virulent bovine viral diarrhea virus type 2 in calves that had maternal antibodies and were vaccinated with a modified-live vaccine.
Zimmerman AD; Boots RE; Valli JL; Chase CC
J Am Vet Med Assoc; 2006 Jun; 228(11):1757-61. PubMed ID: 16740078
[TBL] [Abstract][Full Text] [Related]
2. Effect of maternal antibodies on induction and persistence of vaccine-induced immune responses against bovine viral diarrhea virus type II in young calves.
Ellis J; West K; Cortese V; Konoby C; Weigel D
J Am Vet Med Assoc; 2001 Aug; 219(3):351-6. PubMed ID: 11497051
[TBL] [Abstract][Full Text] [Related]
3. Characterization of protection against systemic infection and disease from experimental bovine viral diarrhea virus type 2 infection by use of a modified-live noncytopathic type 1 vaccine in calves.
Kelling CL; Hunsaker BD; Steffen DJ; Topliff CL; Eskridge KM
Am J Vet Res; 2007 Jul; 68(7):788-96. PubMed ID: 17605616
[TBL] [Abstract][Full Text] [Related]
4. Clinical and immunologic responses of vaccinated and unvaccinated calves to infection with a virulent type-II isolate of bovine viral diarrhea virus.
Cortese VS; West KH; Hassard LE; Carman S; Ellis JA
J Am Vet Med Assoc; 1998 Nov; 213(9):1312-9. PubMed ID: 9810390
[TBL] [Abstract][Full Text] [Related]
5. One year duration of immunity of the modified live bovine viral diarrhea virus type 1 and type 2 and bovine herpesvirus-1 fractions of Vista® Once SQ vaccine.
Purtle L; Mattick D; Schneider C; Smith L; Xue W; Trigo E
Vaccine; 2016 Mar; 34(13):1582-1588. PubMed ID: 26859238
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of multivalent, modified- live virus (MLV) vaccines administered to early weaned beef calves subsequently challenged with virulent Bovine viral diarrhea virus type 2.
Chamorro MF; Walz PH; Passler T; van Santen E; Gard J; Rodning SP; Riddell KP; Galik PK; Zhang Y
BMC Vet Res; 2015 Feb; 11():29. PubMed ID: 25880998
[TBL] [Abstract][Full Text] [Related]
7. Fetal protection against bovine viral diarrhea virus types 1 and 2 after the use of a modified-live virus vaccine.
Xue W; Mattick D; Smith L; Maxwell J
Can J Vet Res; 2009 Oct; 73(4):292-7. PubMed ID: 20046631
[TBL] [Abstract][Full Text] [Related]
8. Maternal antibody blocks humoral but not T cell responses to BVDV.
Endsley JJ; Roth JA; Ridpath J; Neill J
Biologicals; 2003 Jun; 31(2):123-5. PubMed ID: 12770543
[TBL] [Abstract][Full Text] [Related]
9. Comparison of humoral and cellular immune responses to a pentavalent modified live virus vaccine in three age groups of calves with maternal antibodies, before and after BVDV type 2 challenge.
Platt R; Widel PW; Kesl LD; Roth JA
Vaccine; 2009 Jul; 27(33):4508-19. PubMed ID: 19446589
[TBL] [Abstract][Full Text] [Related]
10. The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection.
Kovács F; Magyar T; Rinehart C; Elbers K; Schlesinger K; Ohnesorge WC
Vet Microbiol; 2003 Oct; 96(2):117-31. PubMed ID: 14519330
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of four commercially available multivalent modified-live virus vaccines against clinical disease, viremia, and viral shedding in early-weaned beef calves exposed simultaneously to cattle persistently infected with bovine viral diarrhea virus and cattle acutely infected with bovine herpesvirus 1.
Chamorro MF; Walz PH; Passler T; Palomares R; Newcomer BW; Riddell KP; Gard J; Zhang Y; Galik P
Am J Vet Res; 2016 Jan; 77(1):88-97. PubMed ID: 26709942
[TBL] [Abstract][Full Text] [Related]
12. Effect of passive immunity on the development of a protective immune response against bovine viral diarrhea virus in calves.
Ridpath JE; Neill JD; Endsley J; Roth JA
Am J Vet Res; 2003 Jan; 64(1):65-9. PubMed ID: 12518880
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine.
Fairbanks KK; Rinehart CL; Ohnesorge WC; Loughin MM; Chase CC
J Am Vet Med Assoc; 2004 Dec; 225(12):1898-904. PubMed ID: 15643841
[TBL] [Abstract][Full Text] [Related]
14. Predicted ages of dairy calves when colostrum-derived bovine viral diarrhea virus antibodies would no longer offer protection against disease or interfere with vaccination.
Muñoz-Zanzi CA; Thurmond MC; Johnson WO; Hietala SK
J Am Vet Med Assoc; 2002 Sep; 221(5):678-85. PubMed ID: 12216908
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the onset of protection induced by a modified-live virus vaccine in calves challenge inoculated with type 1b bovine viral diarrhea virus.
Palomares RA; Givens MD; Wright JC; Walz PH; Brock KV
Am J Vet Res; 2012 Apr; 73(4):567-74. PubMed ID: 22452506
[TBL] [Abstract][Full Text] [Related]
16. Development of an APC-targeted multivalent E2-based vaccine against Bovine Viral Diarrhea Virus types 1 and 2.
Pecora A; Malacari DA; Perez Aguirreburualde MS; Bellido D; Nuñez MC; Dus Santos MJ; Escribano JM; Wigdorovitz A
Vaccine; 2015 Sep; 33(39):5163-71. PubMed ID: 26279338
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy of a modified-live combination vaccine against bovine viral diarrhea virus types 1 and 2 challenge exposures in a one-year duration-of-immunity fetal protection study.
Ficken MD; Ellsworth MA; Tucker CM
Vet Ther; 2006; 7(3):283-94. PubMed ID: 17039451
[TBL] [Abstract][Full Text] [Related]
18. Mucosal immune response in newborn Holstein calves that had maternally derived antibodies and were vaccinated with an intranasal multivalent modified-live virus vaccine.
Hill KL; Hunsaker BD; Townsend HG; van Drunen Littel-van den Hurk S; Griebel PJ
J Am Vet Med Assoc; 2012 May; 240(10):1231-40. PubMed ID: 22559114
[TBL] [Abstract][Full Text] [Related]
19. Characterization of protection from systemic infection and disease by use of a modified-live noncytopathic bovine viral diarrhea virus type 1 vaccine in experimentally infected calves.
Kelling CL; Hunsaker BD; Steffen DJ; Topliff CL; Abdelmagid OY; Eskridge KM
Am J Vet Res; 2005 Oct; 66(10):1785-91. PubMed ID: 16273912
[TBL] [Abstract][Full Text] [Related]
20. Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge.
Dean HJ; Leyh R
Vaccine; 1999 Mar; 17(9-10):1117-24. PubMed ID: 10195622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
